Financial Performance - Revenue for 2023 was 1.855 billion yuan, a decrease of 7.47% compared to the previous year[3] - Net profit attributable to shareholders was 202.71 million yuan, an increase of 23.43% year-on-year[3] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 186.47 million yuan, an increase of 47.78% year-on-year[3] - The company's basic earnings per share were 1.51 yuan, an increase of 22.76% compared to the previous year[4] - The company's weighted average return on equity was 10.50%, an increase of 1.42 percentage points year-on-year[4] - Revenue for Q1 2023 was RMB 385.72 million, Q2 was RMB 504.18 million, Q3 was RMB 408.17 million, and Q4 was RMB 556.95 million[34] - Net profit attributable to shareholders in Q1 2023 was RMB 37.50 million, Q2 was RMB 67.42 million, Q3 was RMB 46.82 million, and Q4 was RMB 50.97 million[34] - Non-recurring gains and losses for 2023 totaled RMB 16.24 million, compared to RMB 38.04 million in 2022 and RMB 101.70 million in 2021[38] - Revenue decreased year-over-year, but profitability and profit margins improved significantly due to favorable exchange rates and lower raw material prices[42] - Company achieved consolidated operating revenue of 1,855,029,390.81 yuan, a year-on-year decrease of 7.47%[101] - Net profit attributable to the parent company was 202,706,851.03 yuan, a year-on-year increase of 23.43%[101] - Manufacturing sector revenue decreased by 7.10% to 1,839,119,919.42 RMB, with a gross margin increase of 4.00 percentage points to 30.63%[107] - Service sector revenue decreased by 8.61% to 6,041,520.32 RMB, with a gross margin increase of 39.14 percentage points to 66.74%[107] - Total revenue decreased by 7.10% to 1,845,161,439.74 RMB, with a gross margin increase of 4.11 percentage points to 30.74%[107] - Massage chair revenue decreased by 5.90% to 1,766,407,013.60 RMB, with a gross margin increase of 4.22 percentage points to 31.12%[107] - Small appliance revenue decreased by 28.22% to 72,109,722.82 RMB, with a gross margin decrease of 2.61 percentage points to 19.07%[107] - Top 5 customers accounted for 44.13% of total annual sales, totaling 818,697,800 RMB[111] - Top 5 suppliers accounted for 24.21% of total annual procurement, totaling 245,178,300 RMB[111] - Merchant service revenue decreased by 69.22% to 1,066,603.99 yuan, accounting for 53.08% of total revenue[121] - Direct material costs for massage chairs decreased by 13.04% to 993,968,434.26 yuan, accounting for 81.69% of total costs[121] - Total costs for massage chairs decreased by 11.33% to 1,216,732,886.15 yuan[121] - Direct material costs for small electrical appliances decreased by 25.62% to 56,421,849.75 yuan, accounting for 96.68% of total costs[121] - Total costs for small electrical appliances decreased by 25.83% to 58,359,840.21 yuan[121] - Accounts receivable increased by 61.29% to 153,334,053.36 yuan, accounting for 4.53% of total assets[128] - Short-term borrowings decreased by 68.39% to 129,132,300.71 yuan, accounting for 3.81% of total assets[128] - Other equity investments increased by 212.74% to 93,508,800.00 yuan, accounting for 2.76% of total assets[128] - Estimated liabilities increased by 95.01% to 71,577,930.47 yuan, accounting for 2.11% of total assets[128] - The company's total assets as of December 31, 2023, were 3.385 billion yuan, with a debt-to-asset ratio of 41.71% and a credit rating of AA-[197] R&D and Innovation - The company completed 15 R&D projects, added 15 invention patents, 67 utility model patents, 11 design patents, and 11 software copyrights[1] - The company's S80 massage chair won the 2023 MUSE Design Gold Award, and the RT7730 massage chair won the 2023 MUSE Design Silver Award[1] - R&D expenses were 80,176,150.48 yuan, a year-on-year decrease of 9.57%[102] - The company has 182 R&D personnel, accounting for 16.61% of the total workforce[113] - The company is focusing on AI technology, health detection management, and voice interaction to drive innovation in massage chair technology and maintain a competitive edge[140] - The company aims to create a full product matrix of massage chairs, including ultra-high-end, mid-to-high-end, light luxury, and simple models, to enhance competitiveness in various market segments[140] - The company plans to acquire health-related companies with AI capabilities to integrate emerging technologies like cloud computing and big data into its products[141] - The company is enhancing its R&D capabilities and production automation to develop new products and expand its customer base both domestically and internationally[139] Overseas Expansion and Market Strategy - The company plans to establish a factory in Thailand, with a memorandum of cooperation signed with Suvarnabhumi Asia Industrial Park[2] - The company's online direct sales revenue on Douyin achieved rapid growth[15] - Overseas markets showed mixed performance: South Korea recovered in the second half, the US saw a slight decline, while Europe, the Middle East, and Southeast Asia remained stable, with Russia showing significant growth[46] - The company adjusted its European and Southeast Asian market teams by splitting them into two independent teams to better meet customer needs and explore market potential[46] - The company has expanded its overseas market, with products sold to the US, EU, South Korea, Southeast Asia, and countries along the Belt and Road[99] - The company plans to expand its overseas market presence by developing potential markets in Southeast Asia and Europe, and selling its own brand massage chairs and small appliances through e-commerce platforms like Amazon[140] - The company is establishing an overseas production base in Thailand's Suvarnabhumi Asia Industrial Park to better respond to global uncertainties and effectively expand its international market[140] - The company's export business involves direct sales to overseas clients, who then determine the brand, sales channels, and pricing for the products[83] Cost Control and Efficiency - The company's logistics cost control was effective, with a significant reduction in cargo damage rates[2] - Direct material costs decreased by 13.87% to 1.051 billion RMB, accounting for 82.38% of total manufacturing costs[44] - Manufacturing expenses decreased by 3.77% to 88.617 million RMB, accounting for 6.95% of total manufacturing costs[44] - The company implemented cost reduction and efficiency improvement measures, including optimizing supply chain management and reducing unnecessary expenses[42] - The company is improving production efficiency and supply chain management to reduce unit costs through economies of scale[142] - Depreciation costs decreased by 69.00% to 26,727.34 yuan, accounting for 1.33% of total costs[121] Cash Flow and Financial Activities - Operating cash flow increased by 45.40% to 344.295 million RMB, while financing cash flow decreased by 327.18% to 426.170 million RMB[58] - Net cash flow from operating activities was 344,294,659.84 yuan, a year-on-year increase of 45.40%[102] - Net cash flow from investing activities was 120,962,648.98 yuan, compared to -225,043,933.29 yuan in the same period last year[104] - Net cash flow from financing activities was -426,170,282.03 yuan, a year-on-year decrease of 327.18%[104] - The company plans to use idle funds to purchase financial products and manage cash from convertible bonds in 2023[165] - The company will engage in forward exchange and foreign exchange derivative business in 2023[165] - The company plans to sign financing agreements with banks and use idle funds for financial product purchases in 2023[174] Product Portfolio and Sales Channels - The company optimized its product portfolio through product innovation and customization to meet the needs of different markets and channels[42] - The company's main products include massage chairs and small massage devices, with massage chairs providing a full-body massage experience through software-controlled hardware, and small devices focusing on specific body parts[63] - The company operates in the domestic market through five sales channels: distribution, direct sales, e-commerce, experience stores, and ODM, while its export business primarily uses FOB terms[75][76] - As a leading domestic and global manufacturer of massage chairs, the company has over 1,000 offline stores in China and a strong presence on major e-commerce platforms like Tmall, JD.com, and Suning[77] - The company employs a brand differentiation strategy, with the "Rongtai" brand targeting mid-to-high-end massage chairs and the "Momoda" brand focusing on entry-level products[77] - The company has established a multi-channel marketing strategy, including shopping malls, chain stores, car 4S stores, e-commerce, and experience stores[97] Industry and Market Trends - The massage equipment industry in China has grown from RMB 55.819 billion in 2014 to RMB 95.119 billion in 2023, with the household sector accounting for 56.77% of the market in 2023[80] - In 2023, the company produced 191,760 massage chairs, a decrease of 5.75% year-over-year, and sold 268,344 units, a decrease of 6.25% year-over-year[86] - The company's sales of small massage devices in 2023 were 335,595 units, a decrease of 33.57% year-over-year, with inventory decreasing by 4.03%[86] - The company's performance is driven by increasing demand for health-related products, aging populations, and younger consumers seeking relief from work-related stress[85] Investments and Subsidiaries - Other equity instrument investments increased by RMB 63.61 million in 2023, reaching RMB 93.51 million at year-end[40] - Transactional financial assets decreased by RMB 37.93 million in 2023, ending at RMB 15.11 million[40] - Other non-current financial assets increased by RMB 4.48 million in 2023, totaling RMB 99.55 million at year-end[40] - Transactional financial liabilities increased by RMB 7.46 million in 2023, reaching RMB 12.08 million[40] - The total impact of financial asset and liability changes on 2023 profits was a loss of RMB 11.05 million[40] - Shanghai Rongtai Health Technology Co., Ltd. invested 138.9966 million RMB in Shanghai Miaoyin Network Technology Co., Ltd., achieving a 100% ownership[132] - The company invested 4,750 million RMB in Shanghai Rongchang Lingsi Commercial Factoring Co., Ltd., holding a 95% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 167.31 million RMB in Shaoxi Network Technology Co., Ltd., with a 75% ownership[132] - The company invested 3.5 million USD in BODYFRIEND, INC., holding a 35% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 90 million RMB in Guangdong Momole Network Technology Co., Ltd., with a 30% ownership before exiting in November 2023[132] - The company invested 1,764.50 million RMB in Guangzhou Jinno Intelligent Equipment Co., Ltd., holding a 20% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 920 million KRW in BAHC CO., LTD., with a 7.7% ownership[132] - The company invested 1,885 million RMB in Jiaxing Ouyuan Motor Co., Ltd., holding a 35% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 532.65 million RMB in Shanghai Rongyi Electric Appliance Co., Ltd., achieving 100% ownership[132] - The company invested 200 million RMB in Guangdong Kaixuan Sports Goods Co., Ltd., with a 10% ownership[132] Corporate Governance and Shareholder Relations - The company's 2023 annual general meeting approved several key resolutions, including the 2022 annual report, financial report, and profit distribution plan[165] - The company's board of directors approved the 2022 annual report, financial report, and profit distribution plan during the fourth meeting[174] - The company will not adjust the conversion price of "Rongtai Convertible Bonds" in 2023[174] - The company's board of directors held 9 meetings in the year, with all directors attending all meetings either in person or via communication methods[177] - The Audit Committee held 4 meetings during the reporting period, reviewing the company's annual report and providing relevant suggestions[178] - The company's cash dividend policy for 2024 includes a distribution of RMB 10.00 per 10 shares and a capital reserve transfer of 3 shares per 10 shares[181] - In 2023, the company repurchased and canceled 1 million restricted shares, accounting for 0.71% of the total share capital, due to unmet performance conditions[183] - The company's 2021 restricted stock incentive plan's second unlocking period did not meet performance conditions, resulting in the cancellation of 1 million shares[183] - The company's 2021 management partner shareholding plan's second vesting period also did not meet performance conditions, with corresponding shares to be sold and proceeds returned to the company[183] - The company's salary policy includes different structures for production and non-production staff, with future adjustments based on Shanghai's average wage and company performance[180] - The company's cash dividend policy is in compliance with the articles of association, with clear standards, complete decision-making procedures, and protection of minority shareholders' rights[182] - The company's board of directors and audit committee have been diligent in their duties, with no instances of directors missing two consecutive meetings[177][178] - The company has a cumulative cash dividend payout ratio of 38.99% over the past three years and plans to maintain a stable dividend policy[190] Environmental and Social Responsibility - The company and its subsidiaries have implemented carbon reduction measures, reducing CO2 emissions by 2,193.29 tons[185] - The company has built a 1.7MWp distributed rooftop photovoltaic project, generating approximately 1.81 million kWh annually and reducing CO2 emissions by 1,491.44 tons[185] - Subsidiary Zhejiang Rongtai has built an 800KWp distributed rooftop photovoltaic project, generating approximately 850,000 kWh annually and reducing CO2 emissions by 701.85 tons[186] - The company has maintained a stable production and operation, with steady output value and profit, and has obtained multiple quality and safety certifications[189] - The company has established a comprehensive training system, including the development of the Rongtai University E-learning platform, to enhance employee skills and knowledge[195] - The company has actively participated in community civilization construction, forming partnerships with multiple local organizations and achieving a satisfaction rate of over 95%[199] - The company has consistently engaged in disaster relief and donation activities, being recognized as an advanced unit for voluntary blood donation for 10 consecutive years[200] Human Resources and Compensation - Total compensation for directors, supervisors, and senior management in 2023 was 9.0656 million yuan[153] - The company has a total of 1,096 employees, with 651 production personnel, 104 sales personnel, 182 technical personnel, 36 financial personnel, and 123 administrative personnel[159] - The company's educational composition includes 26 employees with a master's degree or above, 272 with a bachelor's degree, 291 with an associate degree, and 507 with education below an associate degree[159] - The total hours of outsourced labor were 1.9895 million hours, with a total payment of 57.1434 million yuan[160] - The company distributed cash dividends of 26.25 million yuan in 2016, 39.375 million yuan in 2015, and 26.25 million yuan in 2014[161] Risk Management and Strategic Goals - The company faces risks from a high concentration of revenue from its major client, BODYFRIEND, which accounted for a significant portion of its main business revenue[163] - The company is actively developing new products with ODM partners and expanding its market presence in Europe and America beyond South Korea[163] - The company is implementing multiple measures to address industry competition, focusing on product innovation and maintaining a strong brand image[164] - The company's strategic goal is to become a leading international fashion health appliance service provider by leveraging its existing technological, market, and production advantages[139] - The company is committed to innovation in products, services, and business models to optimize global residents' quality of life and achieve sustainable growth[139] - The company is leveraging capital markets to raise funds for expanding production scale and improving technological innovation[139]

www.zhcpa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 上海荣泰健康科技股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23. Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 上海荣泰健康科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了上海荣泰健康科技股份有限公司(以下简称荣泰健康公司)2023年12月31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 内部控制审计报告 中汇会审[2024]3644号 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是荣泰 健康公司董事会的责任。 二、注册会计师的责任 我们的 ...

证券代码：603579 证券简称：荣泰健康 公告编号：2024-023 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为了提高公司闲置自有资金的使用效率，保护股东利益，上海荣泰健康科 技股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日召开第四届董事会 第十四次会议及第四届监事会第十一次会议，审议通过了《关于公司 2024 年度 使用闲置自有资金购买理财产品的议案》，同意公司及公司全资子公司、控股 子公司在确保不影响公司日常经营的情况下，使用最高额度不超过人民币 9 亿 元的闲置自有资金进行投资理财，在上述额度内可循环滚动使用。本议案尚需 提交股东大会审议。具体事宜如下： 一、本次委托理财概况 （一）投资目的 投资种类：银行理财产品、券商理财产品、信托理财产品、其他类 投资金额：不超过人民币 9 亿元 已履行及拟履行的审议程序：本事项经第四届董事会第十四次会议及第四 届监事会第十一 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2024-024 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为了提高公司闲置募集资金的使用效率，保护股东利益，在确保不影响募 集资金安全、不改变募集资金用途和募集资金投资项目资金使用进度安排的前 提下，上海荣泰健康科技股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日召开第四届董事会第十四次会议及第四届监事会第十一次会议，审议通过了 《关于公司 2024 年度使用可转债闲置募集资金进行现金管理的议案》，同意公 司及子公司使用最高不超过人民币 4 亿元的公开发行可转换公司债券（以下简 称"可转债"）闲置募集资金适时投资安全性高、流动性好、低风险的理财产 品或结构性存款，授权期限为自公司股东大会审议通过之日起 12 个月内。在上 述额度及授权期限内，资金可由公司、公司全资 ...

上海荣泰健康科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 www.zhcpa.cn 上海荣泰健康科技股份有限公司全体股东: 我们鉴证了后附的上海荣泰健康科技股份有限公司(以下简称荣泰健康公司) 管理层编制的《关于2023年度募集资金存放与使用情况的专项报告》。 目 录 | 页 次 | | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-3 | | 二、上海荣泰健康科技股份有限公司关于 2023 年度募集资金 | | | | | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New Ci ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2024-025 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于开展远期结售汇业务和外汇衍生产品业务的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024 年 4 月 15 日，上海荣泰健康科技股份有限公司（以下简称"公司"） 召开第四届董事会第十四次会议、第四届监事会第十一次会议，审议通过了《关 于公司开展远期结售汇业务和外汇衍生产品业务的议案》及《关于开展外汇套期 交易目的：由于公司国际业务的外汇收付金额较大，外汇汇率/利率波动对公 司经营成果可能产生较大影响。为减少外汇汇率/利率波动带来的风险，公司 拟开展远期结售汇、外汇期权产品等业务，以降低外汇汇率/利率波动带来的 风险； 交易品种：外汇汇率，包括但不限于美元、欧元、港币、韩元等币种； 交易工具：远期结售汇业务、外汇衍生产品业务； 交易场所：具有合法经营资格的金融机构； 交易金额：不超 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2024-018 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 第四届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海荣泰健康科技股份有限公司（以下简称"公司"）第四届董事会第十四 次会议于 2024 年 4 月 15 日上午 10 时在上海市青浦区徐泾镇高光路 169 弄虹桥 时代广场荣泰大厦公司会议室以现场加通讯表决方式召开。会议通知和材料已于 2024 年 4 月 3 日以现场送达、电话或电子邮件等方式发出。本次会议由董事长 林光荣先生主持，会议应参加董事 9 人，实际参加董事 9 人。公司监事及部分高 级管理人员列席了会议。本次会议的召集、召开程序符合《中华人民共和国公司 法》（以下简称"《公司法》"）等有关法律、法规、《上海荣泰健康科技股份 有限公司章程》（以下简称"《公司章程》"）的规定，会议决议合法、有效。 二、董事会会议审议 ...

| 证券代码：603579 | 证券简称：荣泰健康 公告编号：2024-019 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 第四届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海荣泰健康科技股份有限公司（以下简称"公司"）第四届监事会第十一 次会议于 2024 年 4 月 15 日下午 13 时在上海市青浦区徐泾镇高光路 169 弄虹桥 时代广场荣泰大厦公司会议室召开。会议通知及会议资料已于 2024 年 4 月 3 日 以现场送达、电话或电子邮件等方式发出。本次会议由监事会主席曹韬先生主持， 会议应到监事 3 人，实到监事 3 人。本次会议的召集、召开程序符合《中华人民 共和国公司法》（以下简称"《公司法》"）等有关法律、法规、《上海荣泰健康科 技股份有限公司章程》（以下简称"《公司章程》"）的规定，会议决议合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2023 年年度报告及报告摘要 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2024-021 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于续聘 2024 年度会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 成立日期：2013 年 12 月 19 日 组织形式：特殊普通合伙 注册地址：杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室 首席合伙人：余强 截至 2023 年 12 月 31 日，合伙人数量 103 人，注册会计师人数 701 人，签署过 证券服务业务审计报告的注册会计师人数 282 人。 中汇最近一年（2023 年度）业务收入为 108,764 万元，其中，审计业务收入为 97,289 万元，证券业务收入为 54,159 万元。 拟聘任的会计师事务所名称：中汇会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 企业名称：中汇会计师事务所（特殊普通合 ...

万和证券股份有限公司关于 上海荣泰健康科技股份有限公司 2023 年度募集资金 存放与实际使用情况的专项核查报告 根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号-上市 公司募集资金管理和使用的监管要求》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 1 号—规范运作》和《上海证券交易所上市 公司自律监管指引第 11 号—持续督导》等有关法律法规的要求，万和证券股份 有限公司（以下简称"万和证券"或"保荐机构"）就上海荣泰健康科技股份有限公 司（简称"荣泰健康"、"上市公司"、"公司"）2023 年度募集资金存放与使用情况 进行了核查，情况如下： 一、募集资金基本情况 （一）募集资金金额及到位情况 经中国证券监督管理委员会《关于核准上海荣泰健康科技股份有限公司公开 发行可转换公司债券的批复》（证监许可［2020]2139 号）核准，公司公开发行 600 万张 A 股可转换公司债券（每张面值 100 元人民币），募集资金总额为人民 币 60,000.00 万元。公司扣除剩余部分应支付的承销及保荐费用后，实际收到可 转换公司债券认购资金人民币 59,730.00 万元。该款 ...